2,515 reports of this reaction
4.5% of all DASATINIB reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for DASATINIB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 2,515 FDA adverse event reports linking DASATINIB to FATIGUE. This represents approximately 4.5% of all 55,495 adverse event reports for this drug.
Patients taking DASATINIB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among DASATINIB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for DASATINIB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,515 FDA reports for DASATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 4.5% of all adverse event reports for DASATINIB, making it one of the most commonly reported side effect.
If you experience fatigue while taking DASATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.